BiotechTube

Mirikizumab

Phase 3Active
0 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Crohn's Disease

Conditions

Crohn's Disease

Trial Timeline

Jun 22, 2020 → Apr 1, 2027

NCT ID
NCT04232553

About Mirikizumab

Mirikizumab is a phase 3 stage product being developed by Eli Lilly for Crohn's Disease. The current trial status is active. This product is registered under clinical trial identifier NCT04232553. Target conditions include Crohn's Disease.

What happened to similar drugs?

9 of 20 similar drugs in Crohn's Disease were approved

Approved (9) Terminated (4) Active (11)
✅adalimumabAbbVieApproved
✅Infliximab 5 mg/kg + Infliximab 5 mg/kg every 6 weeks + Infliximab 7 mg/kg every 8 weeksMerckApproved
✅Infliximab + Prednisolone + AzathioprinePfizerApproved
✅Celebrex + placeboPfizerApproved
✅Cimzia + MesalamineUCBApproved
✅Certolizumab PegolUCBApproved
✅certolizumab pegol + certolizumab pegol + certolizumab pegol + certolizumab pegolUCBApproved

Hype Score Breakdown

Clinical
17
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (10)

NCT IDPhaseStatus
NCT07446101Phase 1Recruiting
NCT07059130ApprovedRecruiting
NCT05509777Phase 3Recruiting
NCT05644353Phase 1Completed
NCT05515601Phase 1Completed
NCT04548219Phase 1Completed
NCT04232553Phase 3Active
NCT04004611Phase 2Completed
NCT03556202Phase 3Terminated
NCT03519945Phase 3Active

Competing Products

20 competing products in Crohn's Disease

See all competitors
ProductCompanyStageHype Score
CT-P13 + RemicadeCelltrionPhase 3
40
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13CelltrionPhase 1
29
CT-P13 SC (Infliximab)CelltrionPhase 3
40
CP-461Astellas PharmaPhase 2
35
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kgEisaiPhase 1/2
32
E6011 + PlaceboEisaiPhase 2
35
E6011 + PlaceboEisaiPhase 1
21
adalimumab + adalimumab + placeboEisaiPhase 2/3
38
adalimumabEisaiPhase 2/3
38
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + PlaceboEli LillyPhase 3
40
MirikizumabEli LillyPhase 3
47
Mirikizumab + Mirikizumab + Tirzepatide + PlaceboEli LillyPhase 3
47
Mirikizumab + PlaceboEli LillyPhase 2
35
Matching Placebo for Upadacitinib + UpadacitinibAbbViePhase 3
40
Adalimumab + PlaceboAbbViePhase 3
40
Upadacitinib + Placebo for UpadacitinibAbbViePhase 3
40
Placebo + ABT-494AbbViePhase 2
35
ABT-494AbbViePhase 2
35
Risankizumab + ComparatorAbbViePre-clinical
33
placebo for risankizumab + risankizumab IV + risankizumab SCAbbViePhase 3
40